---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Neonatal fc receptor blockers"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Neonatal fc receptor blockers. Topics: Mechanism, onset, and comparative effect of FcRn blockers: Nordic guidance; Efgartigimod intravenous: FDA-labeled indication, dosing, and pivotal trials; Efgartigimod alfa and hyaluronidase subcutaneous: FDA-labeled indication and dosing; Rozanolixizumab: FDA-labeled indication, dosing, and pivotal trial; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/neonatal-fc-receptor-blockers"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Neonatal fc receptor blockers

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Neonatal Fc Receptor Blockers

<a id="topic-2.2.2.1.7-1"></a>

### Mechanism, onset, and comparative effect of FcRn blockers: Nordic guidance

> “Monoclonal antibodies directed at the FcRn receptor's binding site for IgG block recycling and lead to a 60%–70% reduction in circulating IgG.”
> “The treatment can be tailored according to the disease state; new treatment cycles can be administered with signs of symptom worsening or according to a fixed schedule.”
> “The number of treatment responders and the magnitude of the treatment response for FcRn blockers and complement inhibitors seem to be similar. No prospective and controlled head‐to‐head studies have been undertaken.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.7-2"></a>

### Efgartigimod intravenous: FDA-labeled indication, dosing, and pivotal trials

> “VYVGART is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).”
> “The recommended dosage of VYVGART is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks.”
> “Administer subsequent treatment cycles based on clinical evaluation.”
> “A statistically significant difference favoring VYVGART was observed in the MG-ADL responder rate during the first treatment cycle (67.7% in the VYVGART-treated group vs 29.7% in the placebo- treated group [p <0.0001]).”
> “A statistically significant difference favoring VYVGART was observed (LS mean difference [95% CI] = - 1.46 [-2.50 to -0.41]; p-value = 0.0068).”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.2.2.1.7-3"></a>

### Efgartigimod alfa and hyaluronidase subcutaneous: FDA-labeled indication and dosing

> “VYVGART HYTRULO is indicated for the treatment of adult patients with: • generalized myasthenia gravis (gMG)”
> “The recommended dosage of VYVGART HYTRULO prefilled syringe is 1,000 mg / 10,000 units (1,000 mg efgartigimod alfa and 10,000 units hyaluronidase) administered subcutaneously over approximately 20 seconds to 30 seconds in cycles of once weekly injections for 4 weeks.”
> “VYVGART HYTRULO prefilled syringe may be administered by patients and/or caregivers after proper instruction in subcutaneous injection technique”
> “In Study 3, VYVGART HYTRULO demonstrated a comparable pharmacodynamic effect as compared to the efgartigimod alfa-fcab intravenous formulation, which established the efficacy of VYVGART HYTRULO”

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

<a id="topic-2.2.2.1.7-4"></a>

### Rozanolixizumab: FDA-labeled indication, dosing, and pivotal trial

> “RYSTIGGO (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti- muscle-specific tyrosine kinase (MuSK) antibody positive.”
> “Administer the recommended dosage as a subcutaneous infusion using an infusion pump at a rate of up to 20 mL/hour once weekly for 6 weeks.”
> “A statistically significant difference favoring RYSTIGGO was observed in the MG-ADL total score change from baseline [-3.4 points in RYSTIGGO-treated group at either dose vs -0.8 points in the placebo-treated group (p<0.001)].”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-2.2.2.1.7-5"></a>

### Nipocalimab: FDA-labeled indication, dosing, and pivotal trial

> “generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti- muscle-specific tyrosine kinase (MuSK) antibody positive.”
> “30 mg/kg administered once via intravenous infusion over at least 30 minutes. Two weeks after the initial dose administer a maintenance dose of 15 mg/kg via intravenous infusion over at least 15 minutes. Continue the maintenance dose every two weeks thereafter.”
> “In gMG Study 1, a total of 196 patients were randomized 1:1 to receive IMAAVY (n=98) or placebo (n=98).”
> “Primary Endpoint MG-ADL Total Score1 -4.7 (0.33) -3.3 (0.34) -1.5 (-2.4, -0.5) 0.002”

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-2.2.2.1.7-6"></a>

### Incomplete response to FcRn inhibition

> “Trials of efgartigimod and rozanolixizumab in MG reported a subset of patients who responded poorly despite a reduction in circulating antibodies.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
